Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 141625-93-6
2. Dronedarone Hcl
3. N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)methanesulfonamide Hydrochloride
4. Dronedarone, Hcl
5. Dronedarone (hydrochloride)
6. Dronedarone Hydrochloride [usan]
7. Sr33598b
8. Sr33589 Hydrochloride
9. Dronedarone Hcl (multaq)
10. Fa36dv299q
11. N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide;hydrochloride
12. Sr-33598b
13. 141625-93-6 (hcl); 141626-36-0 (free Base).
14. Methanesulfonamide, N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-, Monohydrochloride
15. N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-benzofuran-5-yl)methanesulfonamide Hydrochloride
16. N-(2-butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) Methanesulfonamide-, Monohydrochloride
17. N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide Hydrochloride
18. Smr003500707
19. Unii-fa36dv299q
20. Dronedarone Hcl
21. Mfcd00914940
22. Multaq (tn)
23. N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide Monohydrochloride
24. Dronedarone Hydrocholoride
25. 4ch-007232
26. Mls004774028
27. Mls006011986
28. Schembl223035
29. Chembl1201729
30. Dronedarone Hydrochloride (usp)
31. Dronedarone Hydrochloride- Bio-x
32. Dtxsid30161779
33. Bcp22474
34. S2114
35. Dronedarone Hydrochloride [mi]
36. Akos005145691
37. Ac-5011
38. Ccg-270168
39. Cs-0712
40. Ks-1260
41. Dronedarone Hydrochloride [mart.]
42. Bd164395
43. Dronedarone Hydrochloride [usp-rs]
44. Dronedarone Hydrochloride [who-dd]
45. Hy-75839
46. N-(2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl)methanesulfonamide Hydrochloride
47. Dronedarone Hydrochloride, >=98% (hplc)
48. D4689
49. Ft-0667799
50. Sw219413-1
51. D03914
52. Dronedarone Hydrochloride [ep Monograph]
53. Dronedarone Hydrochloride [orange Book]
54. Dronedarone Hydrochloride [usp Monograph]
55. A807785
56. J-007525
57. J-520429
58. Q27277877
59. Z1550675452
60. Dronedarone Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
61. Dronedarone Hydrochloride, United States Pharmacopeia (usp) Reference Standard
62. N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]benzofuran-5-yl]methanesulfonamide Hcl
63. 2-n-butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl] 5-methylsulfonamido Benzofuran Hydrochloride
64. Methanesulfonamide, N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]-, Hydrochloride (1:1)
| Molecular Weight | 593.2 g/mol |
|---|---|
| Molecular Formula | C31H45ClN2O5S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 18 |
| Exact Mass | 592.2737714 g/mol |
| Monoisotopic Mass | 592.2737714 g/mol |
| Topological Polar Surface Area | 97.2 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 800 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18409
Submission : 2005-06-08
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-30
Pay. Date : 2013-06-24
DMF Number : 25669
Submission : 2012-02-16
Status : Active
Type : II
Date of Issue : 2024-04-23
Valid Till : 2027-04-22
Written Confirmation Number : WC-0170
Address of the Firm :
Certificate Number : R0-CEP 2019-341 - Rev 00
Issue Date : 2023-04-11
Type : Chemical
Substance Number : 3039
Status : Valid
Date of Issue : 2025-08-08
Valid Till : 2028-08-07
Written Confirmation Number : WC-0424
Address of the Firm :
NDC Package Code : 42413-0060
Start Marketing Date : 2017-12-29
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (36.215kg/36.215kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35913
Submission : 2021-05-31
Status : Active
Type : II
Certificate Number : R0-CEP 2020-266 - Rev 01
Issue Date : 2023-04-27
Type : Chemical
Substance Number : 3039
Status : Valid
Date of Issue : 2022-09-19
Valid Till : 2025-07-02
Written Confirmation Number : WC-0119
Address of the Firm :

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-11-12
Pay. Date : 2013-05-24
DMF Number : 26085
Submission : 2012-06-28
Status : Active
Type : II
Date of Issue : 2022-07-06
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm :
NDC Package Code : 66039-879
Start Marketing Date : 2012-06-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26593
Submission : 2012-12-23
Status : Active
Type : II
Certificate Number : CEP 2022-277 - Rev 00
Issue Date : 2024-03-12
Type : Chemical
Substance Number : 3039
Status : Valid

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-19
Pay. Date : 2013-05-21
DMF Number : 27161
Submission : 2013-05-31
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18409
Submission : 2005-06-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-30
Pay. Date : 2013-06-24
DMF Number : 25669
Submission : 2012-02-16
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-19
Pay. Date : 2013-06-24
DMF Number : 26976
Submission : 2013-03-26
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-11-12
Pay. Date : 2013-05-24
DMF Number : 26085
Submission : 2012-06-28
Status : Active
Type : II

USDMF
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-11
Pay. Date : 2013-04-08
DMF Number : 26901
Submission : 2013-03-26
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27088
Submission : 2013-05-08
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-09-27
Pay. Date : 2013-04-03
DMF Number : 26956
Submission : 2013-03-29
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26023
Submission : 2012-04-25
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26593
Submission : 2012-12-23
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Certificate Number : R0-CEP 2019-341 - Rev 00
Status : Valid
Issue Date : 2023-04-11
Type : Chemical
Substance Number : 3039
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2020-051 - Rev 01
Status : Valid
Issue Date : 2024-01-16
Type : Chemical
Substance Number : 3039

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2020-266 - Rev 01
Status : Valid
Issue Date : 2023-04-27
Type : Chemical
Substance Number : 3039

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2020-033 - Rev 00
Status : Valid
Issue Date : 2022-08-09
Type : Chemical
Substance Number : 3039

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2022-277 - Rev 00
Status : Valid
Issue Date : 2024-03-12
Type : Chemical
Substance Number : 3039

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Date of Issue : 2024-04-23
Valid Till : 2027-04-22
Written Confirmation Number : WC-0170
Address of the Firm : Plot No. 41, 42/2, 42/1/B, 43, 40, 59, 58 GIDC, Vapi, Dist: Valsad -396195, Guja...
Dronedarone Hydrochloride USP/IH
Date of Issue : 2025-08-08
Valid Till : 2028-08-07
Written Confirmation Number : WC-0424
Address of the Firm : Plot No. N-61, Additional Ambernath, Ambernath (East), Dist Thane, Ambernath —...
Date of Issue : 2025-08-22
Valid Till : 2028-08-21
Written Confirmation Number : WC-0082
Address of the Firm : Karakhadi, Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist -Vadodara, Gujara...

Date of Issue : 2022-07-06
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm : Plot No. 3109, GIDC, Industrial Estate Ankleshwar, Distt- Bharuch - 393002, Guja...

Dronedarone Hydrochloride Ph.Eur
Date of Issue : 2025-07-11
Valid Till : 2028-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Sy. No\'s. 52,53,58,59,61 to 78, 127 & 128, Pydibhimavaram Village & Sy. No\'s. ...

Dronedarone Hydrochloride Ph.Eur/USP
Date of Issue : 2022-09-19
Valid Till : 2025-07-02
Written Confirmation Number : WC-0119
Address of the Firm : Plot No. 35, 36, 38, 39, 40, 49, 50 & 51, Phase-IV, IDA, Jeedimetla, Medchal-Mal...

Dronedarone Hydrochloride IH/Ph. Eur
Date of Issue : 2025-07-07
Valid Till : 2028-07-14
Written Confirmation Number : WC-0021
Address of the Firm : Sy. Nos, 317,320,321,322,323,604 & 605, Pincode-502329, Rudraram (Village), Pata...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 42413-0060
Start Marketing Date : 2017-12-29
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (36.215kg/36.215kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66039-879
Start Marketing Date : 2012-06-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 59651-094
Start Marketing Date : 2024-01-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 14593-866
Start Marketing Date : 2023-12-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 14501-0063
Start Marketing Date : 2010-11-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 66022-0118
Start Marketing Date : 2009-07-01
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
About the Company : Unimark Remedies Ltd is a leading API manufacturer with over 18 years of excellence, now fully owned by Shamrock Pharma Group. We provide affordable generic APIs for local and glob...
About the Company : Enaltec, founded in 2006, specializes in developing and manufacturing complex, small-volume, technology-driven APIs at competitive prices, leveraging the India advantage for global...
About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...

About the Company : Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent ...

About the Company : Dalian Richon Chem. Co., Ltd is a high-tech enterprise professionally involved in research and development, manufacturing process and sales service of pharmaceutical intermediates ...

About the Company : In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territo...

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
26
PharmaCompass offers a list of Dronedarone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dronedarone Hydrochloride manufacturer or Dronedarone Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dronedarone Hydrochloride manufacturer or Dronedarone Hydrochloride supplier.
PharmaCompass also assists you with knowing the Dronedarone Hydrochloride API Price utilized in the formulation of products. Dronedarone Hydrochloride API Price is not always fixed or binding as the Dronedarone Hydrochloride Price is obtained through a variety of data sources. The Dronedarone Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride, including repackagers and relabelers. The FDA regulates N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride supplier is an individual or a company that provides N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride active pharmaceutical ingredient (API) or N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride finished formulations upon request. The N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride suppliers may include N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride active pharmaceutical ingredient (API) in detail. Different forms of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride DMFs exist exist since differing nations have different regulations, such as N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride USDMF includes data on N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride suppliers with USDMF on PharmaCompass.
A N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride Certificate of Suitability (COS). The purpose of a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride to their clients by showing that a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CEP has been issued for it. The manufacturer submits a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CEP holder for the record. Additionally, the data presented in the N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride DMF.
A N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride suppliers with CEP (COS) on PharmaCompass.
A N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride written confirmation (N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride WC) is an official document issued by a regulatory agency to a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride manufacturer, verifying that the manufacturing facility of a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride APIs or N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride suppliers with NDC on PharmaCompass.
N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride GMP manufacturer or N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride GMP API supplier for your needs.
A N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CoA (Certificate of Analysis) is a formal document that attests to N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride's compliance with N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride specifications and serves as a tool for batch-level quality control.
N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride EP), N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride USP).